/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

IMMATICS NV

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$10.34 0.0455(4.55%) IMTX at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 9.92
Highest Today 10.505
Today’s Open 9.93
Prev. Close 9.89
52 Week High 11.25
52 Week Low 3.30
Day’s Range: Low 9.92 High 10.505
52-Week Range: Low 3.30 High 11.25
1 day return -
1 Week return -3.22
1 month return +12.06
3 month return +81.03
6 month return +80.08
1 year return +29.59
3 year return -7.54
5 year return -3.67
10 year return -

Institutional Holdings

T. Rowe Price Investment Management,Inc. 15.08

Suvretta Capital Management, LLC 9.90

Baker Bros Advisors LP 8.37

Perceptive Advisors LLC 7.72

RTW INVESTMENTS, LLC 5.73

Vestal Point Capital LP 5.14

Wellington Management Company LLP 4.38

T. Rowe Price Small-Cap Value 3.97

T. Rowe Price Small-Cap Stock 3.29

Woodline Partners LP 3.19

T. Rowe Price US Small-Cap Core Equity 3.15

Paradigm Biocapital Advisors LP 2.59

The Toronto-Dominion Bank 2.40

Morgan Stanley - Brokerage Accounts 2.31

T. Rowe Price U.S. SC Value Eq Tr-D 2.24

Vanguard Explorer Inv 2.18

Sofinnova Ventures 1.84

T. Rowe Price Instl Small-Cap Stock 1.63

T. Rowe Price U.S. SC Core Eq Tr-D 1.54

T. Rowe Price US Smlr Coms Eq A 1.16

Goldman Sachs Group Inc 0.85

Citadel Advisors Llc 0.72

Wasatch Advisors LP 0.65

Wasatch Ultra Growth 0.60

Biotech Growth Ord 0.59

Orbimed Advisors, LLC 0.59

Aberdeen Group PLC 0.59

University Of Texas Investment Mgmt Co 0.57

Sphera Funds Management Ltd. 0.48

683 Capital Management LLC 0.44

International Biotechnology Ord 0.35

abrdn World Healthcare 0.34

abrdn Life Sciences Investors 0.25

Vanguard International Explorer Inv 0.25

Wellington CIF II Small Cap Opps 0.22

Northwestern Mutual Ser Small Cap Value 0.21

T. Rowe Price Small-Cap Value Equity 0.21

Wellington Intl Small Cap Research 0.21

MEDICAL BioHealth EUR Acc 0.20

T. Rowe Price U.S. Equities Tr 0.16

Market Status

Strong Buy: 6

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1202.27 M

PB Ratio 2.6883

PE Ratio 0.0

Enterprise Value 818.78 M

Total Assets 696.15 M

Volume 258813

Company Financials

Annual Revenue FY23:75724000 75.7M, FY22:172831000 172.8M, FY21:34763000 34.8M, FY20:31253000 31.3M, FY19:18449000 18.4M

Annual Profit FY23:null 0.0M, FY22:172831000 172.8M, FY21:34763000 34.8M, FY20:31253000 31.3M, FY19:18449000 18.4M

Annual Net worth FY23:-84078000 -84.1M, FY22:37514000 37.5M, FY21:-95061000 -95.1M, FY20:-229348000 -229.3M, FY19:-31741000 -31.7M

Quarterly Revenue Q3/2025:5187000 5.2M, Q2/2025:4737000 4.7M, Q1/2025:18582000 18.6M, Q3/2024:50559000 50.6M, Q2/2024:18755000 18.8M

Quarterly Profit Q3/2025:5187000 5.2M, Q2/2025:4737000 4.7M, Q1/2025:18582000 18.6M, Q3/2024:50559000 50.6M, Q2/2024:18660140 18.7M

Quarterly Net worth Q3/2025:-50545000 -50.5M, Q2/2025:-70348000 -70.3M, Q1/2025:-39855000 -39.9M, Q3/2024:-8570000 -8.6M, Q2/2024:-18022000 -18.0M

Fund house & investment objective

Company Information Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Organisation Biotechnology

Employees 645

Industry Biotechnology

CEO Dr. Harpreet Singh Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow